Immunotherapy: Care and Prevention of Infectious and Tumoral Diseases (ImmunoHUB)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorFondazione IRCCS Policlinico San Matteo di Pavia
About this trial
The project comprises two research lines. In the line 1, human monoclonal antibodies toward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In the line 2, in vitro tests will be performed to evaluate the efficency of immune response mediated by antibodies direct to specific tumor molecules.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Signed informed consent form Line 2: - Primery liver tumor
Age >18 at time of signing informed consent form
Signed informed consent form
Disqualifiers
Active autoimmune disease ongoing treatment with immunosuppressive therapy
Evidence of positive HIV, HCV, HBV test
Diabetes
Failure to sign informed consent form Line 2: - Concomitant diseases with life expectancy of less than 12 months
Trial population
Line 1: Recovered subjects from SAS-CoV-2 infection. Line 2: Patients with primary liver tumor
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
40 Participants
are grouped into 2 trial groupsGroup A: Recovered subjects after SARS-CoV-2 infection
Group B: Patients with primary liver tumor.
Trial outcomes
Primary outcomes
1
The efficiency of antibodies will be evaluated toward SARS-CoV-2 and liver primary tumor cells by functional in vitro tests.
Time frame
From enrollement to 24 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov